Evolving strategies for the use of combination therapy in hypertension

Gradman, Alan H.; Acevedo, Celso

doi:10.1007/s11906-002-0062-x

Cited by 43 publications

(19 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This treatment has beneficial effects on both morbidity and mortality while, previous general concern on the negative impact of diuretics on the different lipid parameters and metabolic effects appear not justified as, all long-term studies with low-dose diuretics have not been shown to affect lipid and glucose profiles in a negative way [161][162][163]. Moreover, in studies of a year or more duration, diuretics have been shown to reduce cardiovascular risk [145,[164][165][166]. Very recently, it was reported that Chlorthalidone reduced cardiovascular events more than Hydrochlorothiazide, suggesting that Chlorthalidone may be the preferred thiazide-type diuretics for hypertension in patients at a high risk of cardiovascular risk such as in diabetic or obese patients [167].…”

Section: Low Dose Diureticsmentioning

confidence: 99%

Treatments for Hypertension in Type 2 Diabetes-Non-pharmacological and Pharmacological Measurements<sup>#</sup>

Masuo

2015

CHYR

View full text Add to dashboard Cite

Section: Low Dose Diureticsmentioning

confidence: 99%

Treatments for Hypertension in Type 2 Diabetes-Non-pharmacological and Pharmacological Measurements<sup>#</sup>

Masuo

2015

CHYR

View full text Add to dashboard Cite

“…Both of these drugs have shown severe side effects like gastrointestinal disorders, cardiovascular disorders etc eliciting an immediate need to design novel strategies for combating the problem of Obesity [13][14][15]. Since obesity like hypertension is a complex diseases which arises due to multifactorial reasons, so using combination of drugs might prove effective in its treatment [16,17]. So we used two test compounds SAHA and THA in our study.…”

Section: Introductionmentioning

confidence: 99%

Untitled

2017

RJLBPCS

View full text Add to dashboard Cite

ABSTRACT:Obesity is a state characterized by excessive storage of triglycerides in the adipose tissue that leads to the adverse medical consequence. The increasing prevalence and morbidity associated with the disease makes it a serious issue of concern. The treatment regimens for the obesity include diet plans, increase in physical activity, anti-obesity medications and surgery. However The results in totality suggest that the combinational therapy targets key metabolic regulatory pathways like fatty acid synthesis and oxidation, energy homeostasis and adipocyte apoptosis implicating the relevance of therapeutically exploiting the combination treatment for the management of obesity. The combination of SAHA and THA seem to have promising benefits for the treatment and prevention of obesity.

show abstract

“…With combination therapy, however, a lower dose of each agent can be used, thereby alleviating some of the adverse effects. For example, when a dihydropyridine calcium channel blocking agent (DHP-CCB) is combined with an angiotensin-converting enzyme (ACE) inhibitor, the dose-dependent edema induced by the DHP-CCB can be minimized, as a lower dose can be given while still achieving acceptable BP reduction [11].…”

Section: Introductionmentioning

confidence: 99%

Hydrochlorothiazide Versus Calcium Channel Blockers: What is the Best Add-on to a Renin-Angiotensin System Blocker for Treating Hypertension in Patients with Renal Disease?

Lerma

2011

Curr Hypertens Rep

View full text Add to dashboard Cite

Hypertension remains an important problem that increases the risk of cardiovascular disease and is a leading cause of mortality worldwide. Achieving long-term control of arterial hypertension, which has an estimated prevalence of 28% in the US adult population, would translate into a significant reduction in cardiovascular events. Specific causes can be identified and treated for certain forms of secondary hypertension, but often it is multifactorial. Therefore, it makes sense to attain blood pressure control by addressing more than one pressor mechanism. Several clinical studies have demonstrated that combination antihypertensive therapy is more effective than monotherapy, and a review of currently published data suggests that approximately 75% of hypertensive individuals will require some form of combination therapy to achieve target blood pressure (BP) goals. To this end, the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of Blood Pressure (JNC 7) has recommended that antihypertensive therapy should start with two drugs when a patient presents with systolic blood pressure (SBP) more than 20 mm Hg above target levels, diastolic blood pressure (DBP) more than 10 mm Hg above target levels, or both. This review attempts to analyze the current evidence in published medical literature to answer the question of whether hydrochlorothiazide or a calcium channel blocker is a better add-on to a renin-angiotensin system blocker for treating hypertension in patients with renal disease.

show abstract

Evolving strategies for the use of combination therapy in hypertension

Cited by 43 publications

References 20 publications

Treatments for Hypertension in Type 2 Diabetes-Non-pharmacological and Pharmacological Measurements<sup>#</sup>

Treatments for Hypertension in Type 2 Diabetes-Non-pharmacological and Pharmacological Measurements<sup>#</sup>

Untitled

Hydrochlorothiazide Versus Calcium Channel Blockers: What is the Best Add-on to a Renin-Angiotensin System Blocker for Treating Hypertension in Patients with Renal Disease?

Contact Info

Product

Resources

About